ISA Pharmaceuticals’ founder recognised by SITC

Professor Melief

Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). 

The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be presented at the SITC’s 37th Annual Meeting in Boston in November 2022.

Professor Melief, who is Chief Scientific Officer (CSO) and Founder of ISA Pharmaceuticals, will also be inducted as a Fellow of the Academy of Immuno-Oncology (FAIO), one of the SITC’s most prestigious honors.

Gerben Moolhuizen, Chief Executive Officer of ISA Pharmaceuticals, said: “We are very proud that Kees will be receiving two of SITC’s highest honors in recognition of his outstanding contributions to the field of cancer immunotherapy.

“We truly value his dedication to patients and his scientific and medical guidance within our company.” 

Professor Melief is known for his translational work in devising new cancer therapies that activate the patient’s own immune system. In addition to his role at ISA Pharmaceuticals, he is Emeritus Professor of Immunology at the Leiden University Medical Center in the Netherlands.

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free